Envista Q3 sales rise 3.2%, slightly beat estimates

Overview

• Dental products maker's Q3 sales grew 3.2% yr/yr, slightly beating analyst expectations

• Adjusted diluted EPS for Q3 rose 25% yr/yr

• Company raised full-year adjusted EPS guidance

Outlook

• Envista raises 2026 adj EPS guidance to $1.54-$1.58 from $1.50-$1.55

• Company now sees 2026 core sales growth of 3.75%-4.25%

• Envista expects 2026 adj EBITDA growth of 12.5%-14%

Result Drivers

• SEGMENT GROWTH - Co said both Specialty Products & Technologies and Equipment & Consumables segments posted positive core sales growth

• PROCESS IMPROVEMENTS - Envista said its business system contributed to adjusted gross margin and EBITDA margin expansion

Company press release:

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Envista Holdings Corporation is $28.00, about 13% above its November 3 closing price of $24.77

• The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads

• Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook

• Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)